Symptom severity, self-reported adherence, and electronic pill monitoring in poorly adherent patients with bipolar disorder

Martha Sajatovic, Jennifer B. Levin, Johnny Sams, Kristin A. Cassidy, Kouri Akagi, Michelle E. Aebi, Luis F. Ramirez, Steven Safren, Curtis Tatsuoka

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objectives: This analysis of screening and baseline data from an ongoing trial examined self-report versus automated adherence monitoring and assessed the relationship between bipolar disorder (BD) symptoms and adherence in 104 poorly adherent individuals. Methods: Adherence was measured with the Tablets Routine Questionnaire (TRQ) and the Medication Event Monitoring System (MEMS). Symptoms were measured with the Montgomery-Åsberg Depression Rating Scale (MADRS), the Young Mania Rating Scale (YMRS), and the Brief Psychiatric Rating Scale (BPRS). Results: The mean age of the sample was 46.3 years [standard deviation (SD) = 9.41 years], with 72% (n = 75) women and 71% (n = 74) African American subjects. Adherence improved from screening to baseline, with a mean missed drug proportion measured by TRQ of 61.43% (SD = 26.48%) versus a baseline mean of 46.61% (SD = 30.55%). The mean proportion of missed medication using MEMS at baseline was 66.43% (SD = 30.40%). The correlation between TRQ and MEMS was 0.47. The correlation between a single index drug and all BD medications was 0.95. Symptoms were generally positively correlated with TRQ (worse adherence = more severe symptoms), but in most instances was only at a trend level (p > 0.05), with the exception of the correlations between baseline TRQ and MADRS and BPRS, which were positive (r = 0.20 and r = 0.21, respectively) and significant (p ≤ 0.05). Conclusions: In patients with BD, monitoring increased adherence by 15%. MEMS identified 20% more non-adherence than self-report. Using a standard procedure to identify a single index drug for adherence monitoring may be one way to assess global adherence in patients with BD receiving polypharmacy treatment. Greater BD symptom severity may be a clinical indicator to assess for adherence problems.

Original languageEnglish (US)
Pages (from-to)653-661
Number of pages9
JournalBipolar Disorders
Volume17
Issue number6
DOIs
StatePublished - Sep 1 2015
Externally publishedYes

Fingerprint

Bipolar Disorder
Tablets
Brief Psychiatric Rating Scale
Self Report
Polypharmacy
Drug Monitoring
Patient Compliance
Pharmaceutical Preparations
African Americans
Surveys and Questionnaires
Depression

Keywords

  • Adherence
  • Bipolar disorder
  • Compliance
  • Depression
  • Mania
  • Mood stabilizer

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Sajatovic, M., Levin, J. B., Sams, J., Cassidy, K. A., Akagi, K., Aebi, M. E., ... Tatsuoka, C. (2015). Symptom severity, self-reported adherence, and electronic pill monitoring in poorly adherent patients with bipolar disorder. Bipolar Disorders, 17(6), 653-661. https://doi.org/10.1111/bdi.12326

Symptom severity, self-reported adherence, and electronic pill monitoring in poorly adherent patients with bipolar disorder. / Sajatovic, Martha; Levin, Jennifer B.; Sams, Johnny; Cassidy, Kristin A.; Akagi, Kouri; Aebi, Michelle E.; Ramirez, Luis F.; Safren, Steven; Tatsuoka, Curtis.

In: Bipolar Disorders, Vol. 17, No. 6, 01.09.2015, p. 653-661.

Research output: Contribution to journalArticle

Sajatovic, M, Levin, JB, Sams, J, Cassidy, KA, Akagi, K, Aebi, ME, Ramirez, LF, Safren, S & Tatsuoka, C 2015, 'Symptom severity, self-reported adherence, and electronic pill monitoring in poorly adherent patients with bipolar disorder', Bipolar Disorders, vol. 17, no. 6, pp. 653-661. https://doi.org/10.1111/bdi.12326
Sajatovic, Martha ; Levin, Jennifer B. ; Sams, Johnny ; Cassidy, Kristin A. ; Akagi, Kouri ; Aebi, Michelle E. ; Ramirez, Luis F. ; Safren, Steven ; Tatsuoka, Curtis. / Symptom severity, self-reported adherence, and electronic pill monitoring in poorly adherent patients with bipolar disorder. In: Bipolar Disorders. 2015 ; Vol. 17, No. 6. pp. 653-661.
@article{4c147489573e487b96d8529b102a88c8,
title = "Symptom severity, self-reported adherence, and electronic pill monitoring in poorly adherent patients with bipolar disorder",
abstract = "Objectives: This analysis of screening and baseline data from an ongoing trial examined self-report versus automated adherence monitoring and assessed the relationship between bipolar disorder (BD) symptoms and adherence in 104 poorly adherent individuals. Methods: Adherence was measured with the Tablets Routine Questionnaire (TRQ) and the Medication Event Monitoring System (MEMS). Symptoms were measured with the Montgomery-{\AA}sberg Depression Rating Scale (MADRS), the Young Mania Rating Scale (YMRS), and the Brief Psychiatric Rating Scale (BPRS). Results: The mean age of the sample was 46.3 years [standard deviation (SD) = 9.41 years], with 72{\%} (n = 75) women and 71{\%} (n = 74) African American subjects. Adherence improved from screening to baseline, with a mean missed drug proportion measured by TRQ of 61.43{\%} (SD = 26.48{\%}) versus a baseline mean of 46.61{\%} (SD = 30.55{\%}). The mean proportion of missed medication using MEMS at baseline was 66.43{\%} (SD = 30.40{\%}). The correlation between TRQ and MEMS was 0.47. The correlation between a single index drug and all BD medications was 0.95. Symptoms were generally positively correlated with TRQ (worse adherence = more severe symptoms), but in most instances was only at a trend level (p > 0.05), with the exception of the correlations between baseline TRQ and MADRS and BPRS, which were positive (r = 0.20 and r = 0.21, respectively) and significant (p ≤ 0.05). Conclusions: In patients with BD, monitoring increased adherence by 15{\%}. MEMS identified 20{\%} more non-adherence than self-report. Using a standard procedure to identify a single index drug for adherence monitoring may be one way to assess global adherence in patients with BD receiving polypharmacy treatment. Greater BD symptom severity may be a clinical indicator to assess for adherence problems.",
keywords = "Adherence, Bipolar disorder, Compliance, Depression, Mania, Mood stabilizer",
author = "Martha Sajatovic and Levin, {Jennifer B.} and Johnny Sams and Cassidy, {Kristin A.} and Kouri Akagi and Aebi, {Michelle E.} and Ramirez, {Luis F.} and Steven Safren and Curtis Tatsuoka",
year = "2015",
month = "9",
day = "1",
doi = "10.1111/bdi.12326",
language = "English (US)",
volume = "17",
pages = "653--661",
journal = "Bipolar Disorders",
issn = "1398-5647",
publisher = "Blackwell Munksgaard",
number = "6",

}

TY - JOUR

T1 - Symptom severity, self-reported adherence, and electronic pill monitoring in poorly adherent patients with bipolar disorder

AU - Sajatovic, Martha

AU - Levin, Jennifer B.

AU - Sams, Johnny

AU - Cassidy, Kristin A.

AU - Akagi, Kouri

AU - Aebi, Michelle E.

AU - Ramirez, Luis F.

AU - Safren, Steven

AU - Tatsuoka, Curtis

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Objectives: This analysis of screening and baseline data from an ongoing trial examined self-report versus automated adherence monitoring and assessed the relationship between bipolar disorder (BD) symptoms and adherence in 104 poorly adherent individuals. Methods: Adherence was measured with the Tablets Routine Questionnaire (TRQ) and the Medication Event Monitoring System (MEMS). Symptoms were measured with the Montgomery-Åsberg Depression Rating Scale (MADRS), the Young Mania Rating Scale (YMRS), and the Brief Psychiatric Rating Scale (BPRS). Results: The mean age of the sample was 46.3 years [standard deviation (SD) = 9.41 years], with 72% (n = 75) women and 71% (n = 74) African American subjects. Adherence improved from screening to baseline, with a mean missed drug proportion measured by TRQ of 61.43% (SD = 26.48%) versus a baseline mean of 46.61% (SD = 30.55%). The mean proportion of missed medication using MEMS at baseline was 66.43% (SD = 30.40%). The correlation between TRQ and MEMS was 0.47. The correlation between a single index drug and all BD medications was 0.95. Symptoms were generally positively correlated with TRQ (worse adherence = more severe symptoms), but in most instances was only at a trend level (p > 0.05), with the exception of the correlations between baseline TRQ and MADRS and BPRS, which were positive (r = 0.20 and r = 0.21, respectively) and significant (p ≤ 0.05). Conclusions: In patients with BD, monitoring increased adherence by 15%. MEMS identified 20% more non-adherence than self-report. Using a standard procedure to identify a single index drug for adherence monitoring may be one way to assess global adherence in patients with BD receiving polypharmacy treatment. Greater BD symptom severity may be a clinical indicator to assess for adherence problems.

AB - Objectives: This analysis of screening and baseline data from an ongoing trial examined self-report versus automated adherence monitoring and assessed the relationship between bipolar disorder (BD) symptoms and adherence in 104 poorly adherent individuals. Methods: Adherence was measured with the Tablets Routine Questionnaire (TRQ) and the Medication Event Monitoring System (MEMS). Symptoms were measured with the Montgomery-Åsberg Depression Rating Scale (MADRS), the Young Mania Rating Scale (YMRS), and the Brief Psychiatric Rating Scale (BPRS). Results: The mean age of the sample was 46.3 years [standard deviation (SD) = 9.41 years], with 72% (n = 75) women and 71% (n = 74) African American subjects. Adherence improved from screening to baseline, with a mean missed drug proportion measured by TRQ of 61.43% (SD = 26.48%) versus a baseline mean of 46.61% (SD = 30.55%). The mean proportion of missed medication using MEMS at baseline was 66.43% (SD = 30.40%). The correlation between TRQ and MEMS was 0.47. The correlation between a single index drug and all BD medications was 0.95. Symptoms were generally positively correlated with TRQ (worse adherence = more severe symptoms), but in most instances was only at a trend level (p > 0.05), with the exception of the correlations between baseline TRQ and MADRS and BPRS, which were positive (r = 0.20 and r = 0.21, respectively) and significant (p ≤ 0.05). Conclusions: In patients with BD, monitoring increased adherence by 15%. MEMS identified 20% more non-adherence than self-report. Using a standard procedure to identify a single index drug for adherence monitoring may be one way to assess global adherence in patients with BD receiving polypharmacy treatment. Greater BD symptom severity may be a clinical indicator to assess for adherence problems.

KW - Adherence

KW - Bipolar disorder

KW - Compliance

KW - Depression

KW - Mania

KW - Mood stabilizer

UR - http://www.scopus.com/inward/record.url?scp=84940982825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940982825&partnerID=8YFLogxK

U2 - 10.1111/bdi.12326

DO - 10.1111/bdi.12326

M3 - Article

C2 - 26529124

AN - SCOPUS:84940982825

VL - 17

SP - 653

EP - 661

JO - Bipolar Disorders

JF - Bipolar Disorders

SN - 1398-5647

IS - 6

ER -